Primary sclerosing cholangitis

Area of Science:

• Hepatology
• Autoimmune Diseases
• Gastroenterology

Background:

• Primary sclerosing cholangitis (PSC) is a chronic, progressive autoimmune liver disease characterized by bile duct inflammation and fibrosis.
• It often co-occurs with inflammatory bowel disease (IBD), affecting all races and ages, predominantly young males.
• The etiology and pathophysiology remain largely unknown, despite its autoimmune basis.

Purpose of the Study:

• To summarize current knowledge on PSC, including its diagnosis, management, and associated risks.
• To identify unmet medical needs in PSC treatment and patient care.
• To review emerging therapeutic strategies and their potential impact on survival and quality of life.

Main Methods:

• Review of existing literature on PSC epidemiology, pathogenesis, clinical manifestations, and treatment.
• Analysis of diagnostic modalities, including Magnetic Resonance Imaging (MRI) and endoscopic interventions.
• Evaluation of current and investigational therapeutic approaches, encompassing medical, endoscopic, and surgical options.

Main Results:

• PSC leads to bile duct strictures, bacterial cholangitis, liver decompensation, and often necessitates liver transplantation.
• Ursodeoxycholic acid is commonly used for cholestasis but does not improve transplant-free survival.
• Significant research is underway for novel therapies targeting bile acid pathways, inflammation, and the gut microbiome.

Conclusions:

• PSC is a complex autoimmune liver disease with significant morbidity and mortality, lacking approved medical therapies to improve survival.
• Accurate diagnosis via MRI and judicious endoscopic intervention are crucial.
• Ongoing research into novel therapeutics and microbiome manipulation offers hope for improved patient outcomes.